Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Cobenfy, Schizophrenia
Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other antipsychotics.
First New Schizophrenia Treatment Approach In Decades Gets FDA Approval
The US Food and Drug Administration (FDA) has just approved a new drug for the treatment of schizophrenia. Marketed under the name Cobenfy, the medication combines two different drugs that together target a totally different mechanism in the brain than conventional antipsychotics,
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without blocking D2 receptors.
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the first new treatment in decades for the mental health condition that affects 1.8 percent of the U.
Experts hail new schizophrenia drug Cobenfy as a game-changer, the ‘first of its kind’
Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer side effects British scientists have hailed the US approval of a new drug for schizophrenia,
Breakthrough in Schizophrenia Treatment: FDA Approves Cobenfy
New drug offers hope for patients with Schizophrenia that has long eluded effective treatment. Read on to know more.
McKnight's Long-Term Care News
2m
Schizophrenia treatment offers alternative with fewer side effects
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades.
Business Wire
2d
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback